Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | NCOA2 | Q15596 | 2/20 | 0.34 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2681471 | 0.88 | KDM4E (0.38) | ALDH1A1KDM4EMEN1KMT2APOLB | |
| SCHEMBL31720896 | 0.85 | NPC1 (0.34) | ALDH1A1KDM4EPOLBSMN1; SMN2RAB9A | |
| SCHEMBL19206717 | 0.85 | NPC1 (0.34) | ALDH1A1KDM4EPOLBSMN1; SMN2RAB9A | |
| SCHEMBL20543647 | 0.84 | ADORA3 (0.34) | ALDH1A1KDM4ERXFP1POLBSMN1; SMN2 | |
| SCHEMBL492636 | 0.83 | LTB4R (0.41) | ALDH1A1KDM4EPOLBSMN1; SMN2CYP2C9 | |
| SCHEMBL5555425 | 0.82 | KDM4E (0.35) | ALDH1A1KDM4EPOLBSMN1; SMN2RAB9A | |
| SCHEMBL19206645 | 0.82 | POLB (0.35) | ALDH1A1KDM4ERXFP1MEN1KMT2A | |
| SCHEMBL19206719 | 0.81 | ADORA3 (0.35) | RXFP1CDC7 | |
| SCHEMBL19206665 | 0.81 | PDE3B (0.34) | LTA4HALDH1A1KDM4ERXFP1MEN1 | |
| SCHEMBL19206743 | 0.81 | AKR1B1 (0.38) | KDM4ERXFP1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340923-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORP (US) | 2025-11-06 | — | — | US | claimed |
| US-20210254128-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2021-08-19 | — | — | US | claimed |
| US-11015216-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2021-05-25 | — | — | US | claimed |
| US-20200263229-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-08-20 | — | — | US | claimed |
| US-10669568-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2020-06-02 | — | — | US | claimed |
| US-20190241932-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2019-08-08 | — | — | US | claimed |
| EP-3416968-A1 | COELENTERAZINE ANALOGUES | Promega Corporation (US) | 2018-12-26 | — | — | EP | claimed |
| US-20180223330-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-08-09 | — | — | US | claimed |
| WO-2017142852-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION (US) | 2017-08-24 | — | — | WO | claimed |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-08-17 | — | — | US | claimed |
| US-20250340923-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-12391973-B2 | Substituted imidazo[1,2-α]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2025-08-19 | — | — | US | disclosed |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORPORATION | 2024-02-29 | — | — | US | disclosed |
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | PROMEGA CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-20210254128-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2021-08-19 | — | — | US | disclosed |
| EP-3416968-A1 | COELENTERAZINE ANALOGUES | Promega Corporation (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20180223330-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-9924073-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates and preparation method thereof | PROMEGA CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| WO-2017142852-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION (US) | 2017-08-24 | — | — | WO | disclosed |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | CYP4Z1, CYP2E1, CYP2F1 | LTA4H 3941/4885SCN9A 2890/4885ALDH1A1 170/4885 |
| US-20210254128-A1 | COELENTERAZINE ANALOGUES | AADAC, GLB1, PGLS | LTA4H 1482/4885SCN9A 4712/4885ALDH1A1 2295/4885 |
| US-20250340923-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PGLS, AADAC, GLB1 | LTA4H 2135/4885SCN9A 4786/4885ALDH1A1 1179/4885 |
| US-20190241932-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | LTA4H 1694/4885SCN9A 4054/4885ALDH1A1 3541/4885 |
| US-11015216-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | GLB1, PGLS, AADAC | LTA4H 1863/4885SCN9A 4614/4885ALDH1A1 529/4885 |
| US-20180223330-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | LTA4H 1694/4885SCN9A 4054/4885ALDH1A1 3541/4885 |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | LTA4H 1694/4885SCN9A 4054/4885ALDH1A1 3541/4885 |
| US-20200263229-A1 | COELENTERAZINE ANALOGUES | AADAC, GLB1, PGLS | LTA4H 1482/4885SCN9A 4712/4885ALDH1A1 2295/4885 |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PGLS, AADAC, GLB1 | LTA4H 2135/4885SCN9A 4786/4885ALDH1A1 1179/4885 |
| US-10669568-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | AADAC, PGLS, GLB1 | LTA4H 2108/4885SCN9A 4794/4885ALDH1A1 1148/4885 |
| US-12391973-B2 | Substituted imidazo[1,2-α]pyrazines as luciferase substrates | PGLS, GLB1, AADAC | LTA4H 2309/4885SCN9A 4695/4885ALDH1A1 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.